Theresa Marie Koppie MD

Surgical Oncology

Urologist in Portland, Oregon

3303 S Bond AvePortland, OR 97239
Phone+1 503-346-1500
Fax+1 503-346-1501

Dr. Koppie is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Koppie's full profile Already have an account?

Summary

Dr. Theresa Koppie is a urologist based in Portland, OR, with a subspecialty in surgical oncology. She completed her medical education at the Keck School of Medicine of the University of Southern California, followed by surgical and urology residencies at the University of California, San Francisco. Dr. Koppie is experienced in treating prostate cancer, gynecologic oncology, urologic oncology, bladder cancer, and testicular cancer. Her research has been published in notable journals, including The New England Journal of Medicine and JAMA, with significant citations. She has contributed to clinical trials, specifically focusing on bladder cancer treatment. Her work with EpicCare Ambulatory earned her Meaningful Use Stage Certifications from CMS between 2012 and 2015.

Education & Training

University of California (San Francisco)Residency, Urology, 1999 - 2003
University of California (San Francisco)Residency, Surgery, 1997 - 1999
Keck School of Medicine of the University of Southern CaliforniaClass of 1997

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 2026 - 2028
OR State Medical License 2011 - 2027
NY State Medical License 2003 - 2007
American Board of Urology Urology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2015
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2015
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer
COMPLETED
PHASE3

Publications & Presentations

PubMed

21 citations
Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer.
Seth P Lerner, Catherine Tangen, Robert S Svatek, Siamak Daneshmand, Kamal S Pohar
The New England Journal of Medicine. 2024-10-03
14 citations
Development and Multicenter Case-Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction.
Keyan Salari, Debasish Sundi, Jason J Lee, Shulin Wu, Chin-Lee Wu
Clinical Cancer Research. 2023-09-15
13 citations
Urinary Comprehensive Genomic Profiling Correlates Urothelial Carcinoma Mutations with Clinical Risk and Efficacy of Intervention.
Vincent T Bicocca, Kevin G Phillips, Daniel S Fischer, Vincent M Caruso, Mahdi Goudarzi
Journal of Clinical Medicine. 2022-09-30